Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success.

Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with immuno-inflammatory diseases

Arena Pharmaceuticals, Inc. and Pfizer Inc. have entered into a definitive agreement under which Pfizer will acquire Arena.